Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

FOXA1/FOXM1 ChIP-seq on giredestrant-resistant ER+ breast cancer cell lines

ABSTRACT: Characterization of molecular features associated with giredestrant resistance in HR+ breast cancer cell line models

ORGANISM(S): Homo sapiens

PROVIDER: GSE305432 | GEO | 2026/02/13

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

ATACseq on giredestrant-resistant ER+ breast cancer cell lines

Project description:Characterization of molecular features associated with giredestrant resistance in HR+ breast cancer cell line models

2026-02-13 | GSE295128 | GEO

RNAseq on giredestrant-resistant ER+ breast cancer cell lines

Project description:Characterization of molecular features associated with giredestrant resistance in HR+ breast cancer cell line models

2026-02-13 | GSE295127 | GEO

FOXA1/FOXM1 ChIP-seq on giredestrant-resistant ER+ breast cancer cell lines

Project description:FOXA1/FOXM1 ChIP-seq on giredestrant-resistant ER+ breast cancer cell lines

| PRJNA1305728 | ENA

ATACseq on giredestrant-resistant ER+ breast cancer cell lines

Project description:ATACseq on giredestrant-resistant ER+ breast cancer cell lines

| PRJNA1253599 | ENA

RNAseq on giredestrant-resistant ER+ breast cancer cell lines

Project description:RNAseq on giredestrant-resistant ER+ breast cancer cell lines

| PRJNA1253601 | ENA

Transcriptome modulation by long duration giredestrant treatment and the effect of GPX4 CRISPR KO in MCF7 cells

Project description:In the giredestrant resistance/sensitization CRISPR Ko whole genome screen in MCF7 cells, ferroptosis regulator GPX4 comes out as top sensitization hits. We like to see how GPX4 KO changes gene expression profiles, and how giredestrant alone and the combination of GPX4 KO and giredestrant long duration treatment modulate the transcriptome

2024-08-07 | GSE260702 | GEO

T-47D Giredestrant + palbociclib combination TraCe-seq (NGS4327)

Project description:Barcoded clones of T-47D cells were treated with either giredestrant, palbociclib, or their combination for different duration. Barcodes and transcriptional profiles was measured by scRNA-seq.

2025-01-15 | GSE260703 | GEO

RNA-seq of MCF-7 cells with ER or FOXA1 knockout and/or GDC-9545 treatment

Project description:We measured gene expression using RNA-sequencing for MCF-7 cells with and without CRISPR-Cas9-mediated knockout of ER or FOXA1, and in the presence of vehicle or giredestrant (GDC-9545) treatment. RNP is ribonucleoprotein. NTC is non-targeting control.

2026-03-01 | GSE246363 | GEO

T-47D Giredestrant + palbociclib combination TraCe-seq (NGS4327)

Project description:T-47D Giredestrant + palbociclib combination TraCe-seq (NGS4327)

| PRJNA1082726 | ENA

AGR2 and FOXA1 as prognostic markers in ER-positive breast cancer.

Project description:BackgroundThe prognostic role of either forkhead box A1 (FOXA1) or anterior gradient 2 (AGR2) in breast cancer has been found separately. Considering that there were interplays between them depending on ER status, we aimed to assess the statistical interaction between AGR2 and FOXA1 on breast cancer prognosis and examine the prognostic role of the combination of them by ER status.MethodsAGR2 and FOXA1 expression in tumor tissues were evaluated with tissue microarrays by immunohistochemistry in 915 breast cancer patients with follow up data. The expression levels of these two markers were treated as binary variables, and many different cutoff values were tried for each marker. Survival and Cox proportional hazard analyses were used to evaluate the relationship between AGR2, FOXA1 and prognosis, and the statistical interaction between them on the prognosis was assessed on multiplicative scale.ResultsStatistical interaction between AGR2 and FOXA1 on the PFS was significant with all the cutoff points in ER-positive breast cancer patients but not ER-negative ones. Among ER-positive patients, the poor prognostic role of the high level of FOXA1 was significant only in patients with the low level of AGR2, and vice versa. When AGR2 and FOXA1 were considered together, patients with low levels of both markers had significantly longer PFS compared with all other groups.ConclusionsThere was a statistical interaction between AGR2 and FOXA1 on the prognosis of ER-positive breast cancer. The combination of AGR2 and FOXA1 was a more useful marker for the prognosis of ER-positive breast cancer patients.

| S-EPMC10416444 | biostudies-literature

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data